Locations:
Search
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel
Patient with TP53 mutation achieves full response with targeted therapy
Concurrent treatment necessary for addressing progressive disease and infection
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
New system refines classification of cytogenetic abnormalities at time of response assessment and their clinical significance
Lifetime Achievement award-winner reflects on psychosocial support and caregiver readiness
Questions remain about the merits of asparaginase-based therapy
Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities
Age alone should not rule out patients from potentially curative treatment
Advertisement
Advertisement